English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Diamond-Blackfan anemia (DBA) is a rare, genetically determined disorder which is manifested with selective deficiency of erythrocyte line in bone marrow. Patients with DBA are diagnosed with a hypocellular bone marrow with a significant absence of erythroid precursors typically in early childhood. They require chronic treatment with corticosteroids and frequent blood transfusions, stem cell transplantation is also possible. For those., who don’ t respond to corticosteroids therapy, survival depends on blood transfusions. The most common complications of transfusional hemochromatosis are hepatic cirrhosis, cardiomiopathy and endocrinopathies such as hypopitiutarism, hypogonadism, hypothyreosis or diabetes mellitus. DBA patients, therefore, require longterm chelation therapy to avoid these complications.

Hypopituitarism in the course of secondary hemochromatosis in a patient with Diamond-Blackfan anemia